Advanced search×

The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy.

Ladislav L Senolt, Olga O Kryštůfková, Hana H Hulejová, Markéta M Kuklová, Mária M Filková, Lucie Andrés LA Cerezo, Jaromír J Běláček, Martin M Haluzík, Sárka S Forejtová, Steffen S Gay, Karel K Pavelka, and Jiří J Vencovský

Cytokine 55(1):116-21 (2011) PMID 21524918

Visfatin, also known as pre-B cell colony-enhancing factor, was recently characterized as a potent pro-inflammatory mediator in rheumatoid arthritis (RA). The aim of this study was to determine the effect of B cell depletion with rituximab on serum visfatin levels in patients with active RA.

Copyright © 2011 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.cyto.2011.04.004
Version: za2963e q8za0 q8zb3 q8zc0 q8zdb q8ze8 q8zf0 q8zga

Similar articles you may find interesting…

  1. Impact of ankylosing spondylitis on work and family life: comparisons with the US population.
    Michael M MM Ward, John D JD Reveille, ... Michael H MH Weisman

    Arthritis Rheum 59(4):497-503 (2008) PMID 18383414

    Patients with AS were more likely to be work disabled (13.3% versus 5.7%; P < 0.0001) and somewhat more likely to not participate in the labor force compared with the proportion expected (25.1% versus 21.8%; P = 0.07). These associations were stronger among patients age > or =45 years and those with...
  2. Psychological correlates of self-reported disease activity in ankylosing spondylitis.
    Tamar F TF Brionez, Shervin S Assassi, ... Perry P Nicassio

    Journal Watch (General) 37(4):829-34 (2010) PMID 20156952 PMCID PMC2875793

    In the multivariate regression analysis, the psychological variables contributed significantly to the variance in BASDAI scores, adding an additional 33% to the overall R-square beyond that accounted for by demographic and medical variables (combined R-square 18%). Specifically, arthritis helplessne...
    View PDF
  3. [Anti-B-cell strategies in autoimmune diseases].
    U Müller-Ladner

    Z Rheumatol 68(5):363 (2009) PMID 19513728